ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Canaloplasty via an ab-interno approach in primary open-angle glaucoma: Results from a large case series.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness and safety of ab-interno canaloplasty using the iTrack microcatheter in patients with primary open-angle glaucoma (POAG).
methodsThis retrospective, single-center case series included eyes with POAG treated with iTrack ab-interno canaloplasty (Nova Eye Medical, USA), performed either as a standalone procedure or combined with phacoemulsification, with a minimum follow-up of 12 months. Primary outcomes were changes in IOP and number of glaucoma medications. Secondary outcomes included visual acuity (VA), visual field (VF) mean deviation (MD), complications, need for additional glaucoma surgery, and surgical success (as defined by American Academy of Ophthalmology [AAO] criteria). Subgroup analyses were conducted based on disease severity, baseline IOP (≤ 18 mmHg vs. > 18 mmHg), and preoperative medication use (0-4).
resultsBoth standalone (n = 167) and combined (n = 364) procedures achieved significant reductions in IOP and medication use (p < 0.001). At the last follow-up (mean: 20.4 ± 7.7 months), mean IOP was reduced by 3.29 ± 6.0 mmHg in the combined group (from 17.5 ± 5.8 to 14.2 ± 3.8 mmHg) and by 4.50 ± 6.1 mmHg in the standalone group (from 20.2 ± 6.0 to 15.7 ± 4.3 mmHg), with the standalone group showing a significantly greater absolute IOP reduction (p = 0.025). Medication burden was reduced by 1.05 ± 1.06 medications in the combined group and by 0.84 ± 1.15 in the standalone group (p = 0.032). Subgroup analyses confirmed significant IOP and/or medication reductions across all strata, with greater relative benefits in eyes with uncontrolled baseline IOP (> 18 mmHg). Surgical success was 64% in combined and 47% in standalone procedures; success was 75% and 46% in eyes with uncontrolled and controlled baseline IOP. Intraoperative complications were infrequent (1.6%), and 13.1% of eyes required additional glaucoma surgery during follow-up.
conclusionsAb-interno canaloplasty using the iTrack microcatheter, whether as a standalone procedure or combined with phacoemulsification, resulted in sustained reductions in IOP and medication use, with a low rate of complications. These outcomes were consistent across varying levels of disease severity and baseline IOP, with the most pronounced benefits observed in eyes with elevated preoperative IOP.
Indexed as
Identifiers
42189209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.